TOKYO, Jun 05 (Pulse News Wire) – GNI Group Ltd. (2160.T) plans to acquire Aymori Pharmaceutical Holdings' shares worth approximately ¥44.80 billion from Blackstone-led shareholders, aiming to fully integrate the subsidiary.
Aymori's flagship product, Coranaral, holds over 70% share in Japan’s acetaminophen domestic market and is essential in pain management areas. Through this acquisition, GNI Group expects to strengthen its domestic operational base and expand personnel resources. Additionally, it anticipates rapid introduction and expansion of GNI's development products and overseas pharmaceuticals/biosimilars into the domestic market. Aymori's robust sales network and established presence in orthopedic surgery fields further enhance GNI's strategic position.
Aymori Pharmaceutical reported revenues of ¥31.07 billion, ¥34.79 billion, and ¥38.54 billion for fiscal years ending March 2024, March 2025, and March 2026, respectively. Operating profits stood at ¥404 billion, ¥5.452 billion, and ¥6.206 billion during the same periods. As of June 1, 2026, Aymori had around 309 employees. This move aligns with GNI's strategy to establish a large-scale and high-quality pharmaceutical platform in Japan, enhancing its global exposure and reducing geopolitical risks.
It also strengthens networks and expertise in rheumatology, orthopedics, and pain management sectors.
🟡 Confidence: Standard AI-translated content.